Imaging of brain oxygenation with magnetic resonance imaging: A validation with positron emission tomography in the healthy and tumoural brain.

The partial pressure in oxygen remains challenging to map in the brain. Two main strategies exist to obtain surrogate measures of tissue oxygenation: the tissue saturation studied by magnetic resonance imaging (SO-MRI) and the identification of hypoxia by a positron emission tomography (PET) biomarker with 3-[F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([F]-FMISO) as the leading radiopharmaceutical. Nonetheless, a formal validation of SO-MRI against FMISO-PET has not been performed. The objective of our studies was to compare the two approaches in (a) the normal rat brain when the rats were submitted to hypoxemia; (b) animals implanted with four tumour types differentiated by their oxygenation. Rats were submitted to normoxic and hypoxemic conditions. For the brain tumour experiments, U87-MG, U251-MG, 9L and C6 glioma cells were orthotopically inoculated in rats. For both experiments, SO-MRI and [F]-FMISO PET were performed sequentially. Under hypoxemia conditions, SO-MRI revealed a decrease in oxygen saturation in the brain. Nonetheless, [F]-FMISO PET, pimonidazole immunohistochemistry and molecular biology were insensitive to hypoxia. Within the context of tumours, SO-MRI was able to detect hypoxia in the hypoxic models, mimicking [F]-FMISO PET with high sensitivity/specificity. Altogether, our data clearly support that, in brain pathologies, SO-MRI could be a robust and specific imaging biomarker to assess hypoxia.